To Jhild:
In response to your question regarding the "citation with the FDA for NBMX's announced approval of the Verta Line of products," there is an approval number, #973765 510k under the name Bio2000. It has exactly the same product manufacturer as Verta Line, just a different name. Verta Line does not have to clear FDA approval again, we only have to receive a new number. Verta Vac was acquired from Micrilium Laboratories with FDA approval.
To answer your question regarding the following passage:
"VERTAVAC is a uniquely newly developed Bio-Formulation consisting of a synergistic blend of selected activity resulting in a breakdown of tissues, oil, blood, and organic matter in dental evacuation systems."
Verta Vac is an enzymatic and bacterial cleaning solution that is used to clean the dental vacuum systems. It is flushed through the vacuum system, promoting the breakdown of plaque on the vacuum system walls, but does not leave a residue. Verta Vac uses no chemicals and is bio-degradable.
Verta Line and Verta Son do not require FDA approval. All Bontempi instruments are categorized and numbered according to FDA standards; there is no FDA approval necessary.
Be sure to visit our web site at libertycap.com in the next few weeks, as we will be posting new information on NBMX within the next three weeks that should hopefully answer any other questions you might have.
Please feel free to call Tom Raack at Liberty Capital with your questions, 360.676.8072.
Liberty Capital Group, Inc.
research@libertycap.com
libertycap.com
This information is not a solicitation to buy or sell securities. Investors should always consult a registered investment advisor before making any investment decisions.
Liberty Capital Group (LCG) picked National Boston ("the Company") due to the tremendous growth potential in the market for antibacterial products. Additionally, LCG feels that the alliances the Company has developed over the last few months will help propel National Boston to a large and sustained revenue stream.
Due to the above, LCG has agreed to a contract with National Boston as their financial and public relations firm. LCG's contract is a full one year term and will include fees and cash of between $732,000 - $756,000. Due to huge market potential, LCG has agreed to invest up to $500,000 through an option, with prices scaled from $1.00/sh - $7.00/sh.
|
